Quality of life and treatment experience in cancer-related blood clots
Asks people on long-term treatment for cancer-related venous thromboembolism about their daily life and care.
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Houston, United StatesSee the siteAlso in 2 other countries, 3 sites
- Trial code
- Registry title
- Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- Status
- Recruiting
- People taking part
- 260 people, planned
- Started
- 12 Jan 2018
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Treatments tested
- Questionnaires
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cancer who have a blood clot in a leg vein and will take blood thinners for at least 3 months. Participants fill in questionnaires about quality of life, treatment experience and healthcare use.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Confirmed symptomatic blood clot in a deep vein of the leg (deep venous thrombosis), with or without a clot in the lung (pulmonary embolism) or other vein clots. Cancer must be active or diagnosed within 2 years before the clot, confirmed by tissue testing. Basal-cell or squamous-cell skin cancer does not count.
- Earlier treatment
- Must plan to take blood thinners (anticoagulation) for at least 3 months. Must join within the first 5 days after starting blood thinners.
Main reasons for not taking part
- Needing blood thinners for a reason other than a cancer-related clot
- ECOG Performance Status of 4 (completely disabled, in bed or chair all day)
- Life expectancy under 3 months
- Only a lung clot, or a clot only in the arm, abdominal organ veins or brain veins
- Not able to read and speak English
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adult (≥ 18 years) female or male subjects
- Confirmed symptomatic proximal or distal lower extremity deep venous thrombosis with or without pulmonary embolism or other venous thromboses. For a symptomatic lower extremity deep venous thrombosis confirmed by compression ultrasonography, venography, or specific computerized tomography (CT) venography, or a thrombus detected in the iliac veins on an abdominal or pelvic CT. For symptomatic pulmonary embolism confirmed by computerized tomographic pulmonary angiography, ventilation perfusion scan, or catheter pulmonary angiography
- Cancer (other than basal-cell or squamous-cell carcinoma of the skin), either active or diagnosed within 2 years prior to VTE. The diagnosis of cancer must be objectively documented by histopathologic diagnosis
- Intention for long-term treatment (at least 3 months) with anticoagulation
- Participants will be enrolled in the study within the first 5 days from initiation of anticoagulation
- Able to provide informed consent and complete study survey tools
- Able to read and speak English
Who cannot take part
- Indication for anticoagulation other than cancer-related VTE
- Isolated pulmonary embolism, or isolated upper extremity deep venous thrombosis, or isolated splanchnic venous thrombosis, or isolated cerebral venous thrombosis confirmed by compression ultrasonography, venography, or CT
- An Eastern Cooperative Oncology Group (ECOG) Performance Status of 4 at the time of study enrollment
- Life expectancy < 3 months
Where in United States
Also in 2 other countries, 3 sites
- University of Texas - MD Anderson Cancer CenterHouston, United StatesContact: Cristhiam M Rojas Hernandez, MDTaking people
About the trial
What the trial wants to find out
The goal of this research study is to learn about the quality of life, experiences with treatment, and healthcare costs of patients who are receiving long-term treatment for venous thromboembolism (VTE) that is related to cancer.
Read full original descriptionShow less
This is an investigational study. Up to 260 participants will be enrolled in this multicenter study. Up to 170 will take part in MD Anderson.
The group in the trial
- Questionnaires
Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Measurement of Adherence and Health-related Quality of Life, and Health-Care Resource Utilization During Anticoagulation Therapy in Cancer-Related Venous Thromboembolism (VTE)
- Plain-language title
- Quality of life and treatment experience in cancer-related blood clotsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 10 November 2026